Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper

Redondo, Esther; Rivero-Calle, Irene; Mascarós, Enrique; Ocaña, Daniel; Jimeno, Isabel; Gil, Ángel; Linares, Manuel; Onieva-García, María Ángeles; González-Romo, Fernando; Yuste, José; Martinón-Torres, Federico

doi:10.1016/j.arbres.2024.01.004

Cited by 7 publications

(5 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yet, accurately determining RSV morbidity and mortality in older adults is challenging, thus resulting in a substantial under-estimation of the disease burden [ 134 ]. Given the significant burden of RSV-related disease in the elderly, there is an urgent need to develop an effective vaccination strategy, which is why WHO has prioritized the development of an RSV vaccine, emphasizing the importance of vaccination in the adult age [ 138 , 139 ].…”

Section: Resultsmentioning

confidence: 99%

“…A comprehensive literature review by Redondo et al suggested that RSV vaccines should be integrated into routine immunization schedules and that an age-based strategy, i.e., recommending RSV vaccination for all individuals of a certain age regardless of their individual risk, should be prioritized over targeting high-risk groups [ 138 ]. Specifically, adults aged 60 years and older may benefit from RSV vaccination, especially those with chronic diseases, immunosuppression, or institutionalized status.…”

Section: Resultsmentioning

confidence: 99%

“…Considering the geographical and seasonal variations of RSV, the optimal timing of vaccination should be determined according to local surveillance data but as early as possible for those eligible for vaccination. RSV vaccination should be offered to healthcare workers because of the higher risk of contracting and transmitting RSV to their patients [ 138 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Vaccines for the Elderly and Vaccination Programs in Europe and the United States

Anastassopoulou,

Ferous,

Medić

et al. 2024

Vaccines

View full text Add to dashboard Cite

The share of the elderly population is growing worldwide as life expectancy increases. Immunosenescence and comorbidities increase infectious diseases’ morbidity and mortality in older adults. Here, we aimed to summarize the latest findings on vaccines for the elderly against herpes zoster, influenza, respiratory syncytial virus (RSV), COVID-19, and pneumococcal disease and to examine vaccine recommendation differences for this age group in Europe and the United States. PubMed was searched using the keywords “elders” and “vaccine” alongside the disease/pathogen in question and paraphrased or synonymous terms. Vaccine recommendations were also sought in the European and US Centers for Disease Control and Prevention databases. Improved vaccines, tailored for the elderly, mainly by using novel adjuvants or by increasing antigen concentration, are now available. Significant differences exist between immunization policies, especially between European countries, in terms of the recipient’s age, number of doses, vaccination schedule, and implementation (mandatory or recommended). Understanding the factors that influence the immune response to vaccination in the elderly may help to design vaccines that offer long-term protection for this vulnerable age group. A consensus-based strategy in Europe could help to fill the gaps in immunization policy in the elderly, particularly regarding vaccination against RSV and pneumococcus.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Vaccines for the Elderly and Vaccination Programs in Europe and the United States

Anastassopoulou,

Ferous,

Medić

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…The achieved results hold significant value in establishing guidelines cantered on preventive measures for individuals at a higher risk of RSV infection and its consequences. Disseminating these findings to public health policymakers and practitioners can indeed assist in developing shared evidence-based strategies that contribute to strengthening future RSV immunization programs, particularly in high-risk groups [58].…”

Section: Discussionmentioning

confidence: 99%

Respiratory Syncytial Virus (RSV) and Intention to Recommend RSV Vaccination: A Cross-Sectional Survey of Cardiologists and Cardiac Nurses in Southern Italy

Ponticelli,

Losa,

Antonazzo

et al. 2024

Infectious Disease Reports

View full text Add to dashboard Cite

As respiratory syncytial virus (RSV) vaccine distribution gains traction in Europe and Italy, healthcare workers (HCWs) can strategize about vaccine promotion to increase uptake among patients at risk of RSV consequences, such cardiac patients. This cross-sectional survey investigated the knowledge about and attitude towards RSV and RSV vaccines, and the intention to recommend vaccination within a cardiological hospital in Italy. To explore factors associated with the outcomes of interest, multivariate logistic regression analyses were conducted. Of 197 invited HCWs, 78.2% returned the survey. The knowledge about market authorisation for new RSV vaccines for older adults (present in 46.9% of respondents) was significantly associated with the HCWs’ age, education, and previous update on vaccinations. HCWs with a higher educational level and those with a positive attitude towards RSV vaccines safety reported a higher attitude towards the importance of vaccinating people at risk. The willingness of recommending RSV vaccination to patients (70.5% of respondents) was more likely in HCWs who were knowledgeable about market authorisation for RSV vaccines and in physicians. This tempestive research sheds light on current factors influencing the strategies of cardiac HCWs regarding RSV vaccination. The results suggest the need for training events on the protective role of RSV vaccination in cardiac patients.

show abstract

“…In Spain, the Spanish NeumoExperts Prevention Group (NEP) recommends this vaccination among adults over 60 years old, prioritizing those with chronic comorbidities deemed at high risk of severe RSV illness, as well as healthcare workers, who are at elevated risk of both acquiring and transmitting RSV [ 113 ].…”

Section: Management and Preventionmentioning

confidence: 99%

Respiratory Syncytial Virus Infection in Older Adults: An Update

Alfano,

Bigoni,

Caggiano

et al. 2024

Drugs Aging

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) infection represents one of the most common infections during childhood, with significant morbidity and mortality in newborns and in the early years of life. RSV is a common infection throughout all age groups, largely undetected and underestimated in adults, with a disproportionately high impact in older individuals. RSV infection has a wide range of clinical presentations, from asymptomatic conditions to acute pneumonia and severe life-threatening respiratory distress, including exacerbations of underlying chronic conditions. Overall, the incidence of RSV infections requiring medical attention increases with age, and it is highest among persons ≥ 70 years of age. As a consequence of a combination of an aging population, immunosenescence, and the related increased burden of comorbidities, high-income countries are at risk of developing RSV epidemics. The standard of care for RSV-infected patients remains supportive, including fluids, antipyretics, and oxygen support when needed. There is an urgent need for antivirals and preventive strategies in this population, particularly in individuals at higher risk of severe outcomes following RSV infection. In this review, we describe prevention and treatment strategies for RSV illnesses, with a deep focus on the novel data on vaccination that has become available (Arexvy, GSK, and Abrysvo, Pfizer) for older adults.

show abstract

Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper

Cited by 7 publications

References 58 publications

Vaccines for the Elderly and Vaccination Programs in Europe and the United States

Vaccines for the Elderly and Vaccination Programs in Europe and the United States

Respiratory Syncytial Virus (RSV) and Intention to Recommend RSV Vaccination: A Cross-Sectional Survey of Cardiologists and Cardiac Nurses in Southern Italy

Respiratory Syncytial Virus Infection in Older Adults: An Update

Contact Info

Product

Resources

About